von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388:310–8.

Article  Google Scholar 

FDA approves once-weekly ALTUVIIIO™ A new class of factor VIII therapy for hemophilia A that offers significant bleed protection. Paris and Stockholm: Sanofi; 2023.

Pharmacoeconmic Report: Emicizumab (HEMLIBRA). 2021. February 2021.

Abdelgawad HAH, Foster R, Otto M. Nothing short of a revolution: novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A. Blood Rev. 2024;64: 101164.

Article  CAS  PubMed  Google Scholar 

Yu JK, Wong WWL, Keepanasseril A, Iorio A, Edginton AN. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 2023;29:488–97.

Article  CAS  PubMed  Google Scholar 

Decker-Palmer M, Lin C-W, Wilson M, et al. Cost-effectiveness of emicizumab for prophylaxis in people with severe hemophilia A without inhibitors. Blood. 2022;140:13041–2.

Article  Google Scholar 

Blair HA. Emicizumab: a review in haemophilia A. Drugs (New York, NY). 2019;79:1697–707.

Google Scholar 

Camelo RM, Barbosa MM, Araújo MS, et al. Economic evaluation of immune tolerance induction in children with severe hemophilia A and high-responding inhibitors: a cost-effectiveness analysis of prophylaxis with emicizumab. Value Health Reg Issues. 2023;34:31–9.

Article  PubMed  Google Scholar 

Al-Rahal N, Ahmed OAN, Alwataify S, Almusawi IM. Emicizumab prophylaxis every four weeks among hemophilia A with inhibitors in Iraq, multicenter study. J Reattach Ther Dev Diversities. 2022;5:477–82.

Google Scholar 

Cortesi PA, Castaman G, Trifirò G, et al. PRO28 Emicizumab prophylaxis in haemophilia A patients with inhibitors: a cost-effectiveness and budget impact analysis. Value Health. 2019;22:S845.

Article  Google Scholar 

Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task Force–1. Med Decis Mak. 2012;32:667–77.

Article  Google Scholar 

Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Mak. 2012;32:733–43.

Article  Google Scholar 

Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Value Health. 2012;15:804–11.

Article  PubMed  PubMed Central  Google Scholar 

Rind DM, Agboola F, Herron-Smith S, Quach D, Chapman R, Pearson SD. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value (2020)

Gouw SC, Timmer MA, Srivastava A, et al. Measurement of joint health in persons with haemophilia: a systematic review of the measurement properties of haemophilia-specific instruments. Haemophilia. 2019;25:e1–10.

Article  PubMed  Google Scholar 

Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ. 2020;23:501–12.

Article  PubMed  Google Scholar 

Fischer K, Lewandowski D, Janssen MP. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. Haemophilia Off J World Fed Hemoph. 2016;22:e375–82.

CAS  Google Scholar 

Poonnoose PM, Hilliard P, Doria AS, et al. Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia Off J World Fed Hemoph. 2016;22:925–33.

Article  CAS  Google Scholar 

Bolous NS, Chen Y, Wang H, et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood. 2021;138:1677–90.

Article  CAS  PubMed  Google Scholar 

Kragh N, Tytula A, Pochopien M, et al. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK. Eur J Haematol. 2023;110:262–70.

Article  CAS  PubMed  Google Scholar 

Curtis R, Decker-Palmer M, Wilson MR, et al. Cost-effectiveness of emicizumab vs efanesoctocog alfa, standard half life (SHL) and other extended half life (EHL) FVIII products for prophylaxis in people with severe hemophilia a without inhibitors. Blood. 2023;142:5053.

Article  Google Scholar 

Ito S, Potnis KC, Allen C, et al. Equitable care for severe hemophilia_A: distributional cost-effectiveness of prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in patients with severe hemophilia_A in the United States. Blood. 2023;142:492.

Article  Google Scholar 

Hirniak SE, Iorio A, Alsabbagh M, Hajducek D, Wong W. Health utilities in adults with hemophilia A: a retrospective cohort study. Haemophilia. 2024;30:733–42.

Article  PubMed  Google Scholar 

Iorio A, Keepanasseril A, Foster G, et al. Development of a web-accessible population pharmacokinetic service—Hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc. 2016;5: e239.

Article  PubMed  PubMed Central  Google Scholar 

Hirniak S, Edginton AN, Iorio A, Alsabbagh MW, Hajducek DM, Wong WW. Health utilities in adults with hemophilia A: a retrospective cohort study. Haemophilia. 2024;30:733–42.

Article  PubMed  Google Scholar 

Factor VIII concentrates. In: RED BOOK. Merative. https://www.micromedexsolutions.com/. Accessed 24 May 2024.

Statistics C. Purchasing power parities, 2019. Vol 2021. 2020.

Getting Health Care: Wait Times. Ontario Health; 2023. https://www.ontariohealth.ca/public-reporting/wait-times. Accessed 12 Sept 2024.

St-Louis J, Abad A, Funk S, et al. The Hemophilia Joint Health Score version 2.1 validation in adult patients study: a multicenter international study. Res Pract Thromb Haemost. 2022;6:e12690.

Article  PubMed  PubMed Central  Google Scholar 

Osooli M, Steen Carlsson K, Baghaei F, et al. The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register. Haemophilia. 2017;23:e180–7.

Article  CAS  PubMed  Google Scholar 

Hart A, Antoniou J, Brin YS, Huk OL, Zukor DJ, Bergeron SG. Simultaneous bilateral versus unilateral total knee arthroplasty: a comparison of 30-day readmission rates and major complications. J Arthroplasty. 2016;31:31–5.

Article  PubMed  Google Scholar 

Bohm ER, Molodianovitsh K, Dragan A, et al. Outcomes of unilateral and bilateral total knee arthroplasty in 238,373 patients. Acta Orthop. 2016;87(Suppl 1):24–30.

Article  PubMed  PubMed Central  Google Scholar 

Kuijlaars IAR, Timmer MA, de Kleijn P, Pisters MF, Fischer K. Monitoring joint health in haemophilia: factors associated with deterioration. Haemophilia. 2017;23:934–40.

Article  CAS  PubMed  Google Scholar 

Carroll L, Benson G, Lambert J, Benmedjahed K, Zak M, Lee XY. Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom. Patient Prefer Adherence. 2019;13:941–57.

Article  PubMed  PubMed Central  Google Scholar 

Statistics C. Life Tables, Canada, Provinces and Territories, 1980/1982 to 2017/2019. Ottawa: Government of Canada; 2020.

Hassan S, Monahan RC, Mauser-Bunschoten EP, et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018. J Thromb Haemost. 2021;19:645–53.

Article  PubMed  Google Scholar 

Hegde A, Nair R, Upadhyaya S. Spontaneous intracerebral hemorrhage in hemophiliacs-A treatment dilemma. Int J Surg Case Rep. 2016;29:17–9.

Article  PubMed  PubMed Central  Google Scholar 

Rind DM, Agboola F, Herron-Smith S, Quach D, Chapman R, Pearson SD, Bradt P. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value. Institute for Clinical and Economic Review; 2020. 20 Nov 2020.

Heemstra HE, Zwaan T, Hemels M, et al. Cost of severe haemophilia in Toronto. Haemophilia Off J World Fed Hemoph. 2005;11:254–60.

Article  CAS  Google Scholar 

CJRR annual report: Hip and knee replacements in Canada CIHI; 2021.

Xie F, Pullenayegum E, Gaebel K, et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54:98–105.

Article  PubMed  Google Scholar 

Foppen W, van der Schaaf IC, Beek FJA, Verkooijen HM, Fischer K. Scoring haemophilic arthropathy on X-rays : improving inter- and intra-observer reliability and agreement using a consensus atlas. Eur Radiol. 2016;26:1963–70.

Article  PubMed  Google Scholar 

Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2:1792–8.

Article  CAS  PubMed  PubMed Central